# CTI BioPharma clinical trials: 38 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 38 trials with CTI BioPharma as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CTI BioPharma: 38 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cti-biopharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 38
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 38, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 20, 2022 | NCT05657613 | Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects | CTI BioPharma | Phase 1 | Completed | Drug Interactions | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05657613) |
| September 23, 2022 | NCT05552183 | Study to Evaluate the Safety, Tolerability, and PK of Pacritinib | CTI BioPharma | Phase 1 | Completed | Hepatic Impairment | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05552183) |
| May 12, 2021 | NCT04884191 | Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis... | CTI BioPharma | Phase 2 | Completed | Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04884191) |
| May 27, 2020 | NCT04404361 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | CTI BioPharma | Phase 2 | Terminated | COVID19, COVID-19, COVID | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04404361) |
| July 6, 2016 | NCT02823171 | To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy... | CTI BioPharma | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02823171) |
| June 21, 2016 | NCT02808455 | Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy... | CTI BioPharma | Phase 1 | Completed | Healthy Subjects | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02808455) |
| June 21, 2016 | NCT02807207 | To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects | CTI BioPharma | Phase 1 | Completed | Healthy Subjects | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02807207) |
| June 21, 2016 | NCT02807116 | Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy... | CTI BioPharma | Phase 1 | Completed | Healthy Subjects | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02807116) |
| June 21, 2016 | NCT02807077 | PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects | CTI BioPharma | Phase 1 | Completed | Myelofibrosis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02807077) |
| June 21, 2016 | NCT02807051 | To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects | CTI BioPharma | Phase 1 | Completed | Drug Interaction Study | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02807051) |
| June 17, 2016 | NCT02803762 | Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib | CTI BioPharma | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02803762) |
| June 15, 2016 | NCT02800889 | Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | CTI BioPharma | Phase 1 | Withdrawn | Lymphoma, Solid Tumor (Excluding CNS) | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02800889) |
| May 9, 2016 | NCT02765724 | Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects | CTI BioPharma | Phase 1 | Completed | Myelofibrosis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02765724) |
| February 5, 2014 | NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | CTI BioPharma | Phase 3 | Terminated | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 311 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02055781) |
| January 23, 2013 | NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | CTI BioPharma | Phase 3 | Terminated | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 327 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01773187) |
| July 11, 2012 | NCT01638442 | Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects | CTI BioPharma | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01638442) |
| July 3, 2012 | NCT01632436 | Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment | CTI BioPharma | Phase 1 | Withdrawn | Metastatic Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01632436) |
| March 23, 2011 | NCT01321541 | Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular... | CTI BioPharma | Phase 3 | Completed | Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01321541) |
| December 19, 2007 | NCT00577161 | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | CTI BioPharma | Phase 3 | Withdrawn | Non-Hodgkin's Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00577161) |
| December 19, 2007 | NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol \> 25 pg/mL | CTI BioPharma | Phase 3 | Withdrawn | NSCLC | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00576225) |
| October 31, 2007 | NCT00551733 | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung... | CTI BioPharma | Phase 3 | Terminated | Lung Cancer | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00551733) |
| October 30, 2007 | NCT00551239 | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | CTI BioPharma | Phase 3 | Withdrawn | Leukemia, Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00551239) |
| February 15, 2006 | NCT00291837 | CT-2106 for the Second Line Treatment of Ovarian Cancer | CTI BioPharma | Phase 2 | Completed | Ovarian Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00291837) |
| February 15, 2006 | NCT00291785 | Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer | CTI BioPharma | Phase 1/2 | Completed | Colorectal Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00291785) |
| December 26, 2005 | NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. | CTI BioPharma | Phase 3 | Terminated | NSCLC | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00269828) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 2 |
| Phase 2 | 9 |
| Phase 3 | 13 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Terminated | 13 |
| Withdrawn | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Primary Myelofibrosis | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Lymphoma, Follicular | 4 |
| Lung Neoplasms | 4 |
| Lymphoma | 3 |
| Myeloproliferative Disorders | 3 |
| Recurrence | 3 |
| Leukemia | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Multiple Myeloma | 2 |
| Neoplasms, Plasma Cell | 2 |
| Ovarian Neoplasms | 2 |
| Polycythemia Vera | 2 |
| Thrombocythemia, Essential | 2 |
| Bone Marrow Diseases | 2 |
| Hematologic Diseases | 2 |
| Splenomegaly | 2 |
| Anemia | 2 |
| Thrombocytopenia | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Myelodysplastic Syndromes | 1 |
| Myelodysplastic-Myeloproliferative Diseases | 1 |
| Anemia, Refractory | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [Plastics companies in the United States](https://specstream.ai/data/businesses/plastics-companies/united-states)
- [Pediatric surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-surgery-practices/united-states)
- [Pathology practices in the United States](https://specstream.ai/data/businesses/pathology-practices/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
